MYIA
NVCR icon

Mount Yale Investment Advisors’s NovoCure NVCR Stock Holding History

Mount Yale Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-324
Closed -$11K – 619
2018
Q3 		$11K Buy
+324
New +$12.9K ﹤0.01% 849

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Mount Yale Investment Advisors's NVCR Position: Q4 2018 in Review

Mount Yale Investment Advisors sold out of NovoCure (NVCR) in Q4 2018, closing a stake of 324 shares — an estimated $11K sold.

Mount Yale Investment Advisors first reported a position in NVCR in Q3 2018 and held it in 1 quarter. The position peaked at $11K in Q3 2018. 166 funds tracked by Wall St. Rank hold NVCR as of Q4 2018.

  • Mount Yale Investment Advisors reported no remaining NovoCure position as of Q4 2018 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 324 NovoCure shares in Q4 2018, an estimated $11K.
  • Mount Yale Investment Advisors first reported a position in NovoCure in Q3 2018 and held it in 1 quarter.
  • Mount Yale Investment Advisors's NovoCure position peaked at $11K in Q3 2018.
  • 166 funds tracked by Wall St. Rank held NovoCure as of Q4 2018.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.